Literature DB >> 27577947

Gut Microbiota of Obese, Type 2 Diabetic Individuals is Enriched in Faecalibacterium prausnitzii, Akkermansia muciniphila and Peptostreptococcus anaerobius after Weight Loss.

Marlene Remely1, Berit Hippe, Julia Zanner, Eva Aumueller, Helmuth Brath, Alexander G Haslberger.   

Abstract

BACKGROUND: Beside the influence of nutritional habits and reduced physical activity, metabolic syndrome is associated with alterations in the structure of gut microbiota influencing the inflammatory immune responses. Gut microbiota and microbial metabolic activities are known to affect the lipid and glucose metabolism, satiety and chronic low-grade inflammation in the metabolic syndrome. The aim of the study was to identify genera or even species affecting host metabolism in obesity and type 2 diabetes beside the common used indicator: Firmicutes/ Bacteroidetes ratio.
METHODS: Differences in gut microbiota were investigated in three groups of subjects over a four month intervention period: type 2 diabetics under GLP1-Agonist therapy, obese individuals without established insulin resistance, both receiving nutritional counseling concerning weight reduction, and a lean control group. Collection of fecal samples was accomplished at two time points, before treatment, and after four months of treatment. For identification of bacteria at species-level we used 454 high-throughput sequencing and fragment length polymorphism analysis based on IS-pro (Intergenic-Spacer-profiling). Five bacterial species, two bacterial genera, total bacterial abundance, and the Firmicutes/Bacteroidetes ratio were determined.
RESULTS: Type 2 diabetics showed a higher Firmicutes/Bacteroidetes ratio even with an increase to the second time point (p=0.07). The abundance of B. thetaiotaomicron remained unaffected, whereas B. vulgatus significantly increased in type 2 diabetics (p=0.07) over the study period. Either Alistipes spp. showed an increase in type 2 diabetics between the time points (p=0.06). The abundance of F. prausnitzii (p=0.03) and A. muciniphila (p=0.03) also increased in type 2 diabetics over study period. In addition, the concentration of P. anaerobius (p=0.03) was significantly higher in type 2 diabetics after intervention compared to lean and obese controls.
CONCLUSION: Our results clearly show a difference in the gut bacterial composition in type 2 diabetics compared to lean controls or obesity. Therefore, the ratio of Fimicutes/Bacteroidetes might only be an indicator, but a detailed view at species level is even more important in regard to distinction of their functions. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Firmicutes/Bacteroidetes ratio; GLP-1 Agonist therapy; fragment length polymorphism analysis; metabolic syndrome

Year:  2016        PMID: 27577947     DOI: 10.2174/1871530316666160831093813

Source DB:  PubMed          Journal:  Endocr Metab Immune Disord Drug Targets        ISSN: 1871-5303            Impact factor:   2.895


  48 in total

1.  Changes in Weight Status and the Intestinal Microbiota Among College Freshman, Aged 18 Years.

Authors:  Elizabeth K Journey; Carmen P Ortega-Santos; Meg Bruening; Corrie M Whisner
Journal:  J Adolesc Health       Date:  2019-08-30       Impact factor: 5.012

2.  Gut Microbial Predictors of Type 2 Diabetes Remission Following Bariatric Surgery.

Authors:  Naomi Davies; Justin M O'Sullivan; Lindsay D Plank; Rinki Murphy
Journal:  Obes Surg       Date:  2020-09       Impact factor: 4.129

3.  Comparative transcriptome and microbiota analyses provide new insights into the adverse effects of industrial trans fatty acids on the small intestine of C57BL/6 mice.

Authors:  Can Li; Yuhan Zhang; Yueting Ge; Bin Qiu; Di Zhang; Xianshu Wang; Wei Liu; Haiteng Tao
Journal:  Eur J Nutr       Date:  2020-06-20       Impact factor: 5.614

4.  Timing of food intake impacts daily rhythms of human salivary microbiota: a randomized, crossover study.

Authors:  María Carmen Collado; Phillip A Engen; Cristina Bandín; Raúl Cabrera-Rubio; Robin M Voigt; Stefan J Green; Ankur Naqib; Ali Keshavarzian; Frank A J L Scheer; Marta Garaulet
Journal:  FASEB J       Date:  2018-01-05       Impact factor: 5.191

5.  Changes in Gut Microbiome after Bariatric Surgery Versus Medical Weight Loss in a Pilot Randomized Trial.

Authors:  Clare J Lee; Liliana Florea; Cynthia L Sears; Nisa Maruthur; James J Potter; Michael Schweitzer; Thomas Magnuson; Jeanne M Clark
Journal:  Obes Surg       Date:  2019-10       Impact factor: 4.129

6.  A Distinct Brain-Gut-Microbiome Profile Exists for Females with Obesity and Food Addiction.

Authors:  Tien S Dong; Emeran A Mayer; Vadim Osadchiy; Candace Chang; William Katzka; Venu Lagishetty; Kimberly Gonzalez; Amir Kalani; Jean Stains; Jonathan P Jacobs; Valter D Longo; Arpana Gupta
Journal:  Obesity (Silver Spring)       Date:  2020-08       Impact factor: 5.002

7.  Polyphenol- and Caffeine-Rich Postfermented Pu-erh Tea Improves Diet-Induced Metabolic Syndrome by Remodeling Intestinal Homeostasis in Mice.

Authors:  Xiaoyu Gao; Qiuhong Xie; Ping Kong; Ling Liu; Sheng Sun; Boyu Xiong; Baojia Huang; Liang Yan; Jun Sheng; Hongyu Xiang
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

Review 8.  Probiotic strains and mechanistic insights for the treatment of type 2 diabetes.

Authors:  Christiane S Hampe; Christian L Roth
Journal:  Endocrine       Date:  2017-10-19       Impact factor: 3.633

9.  Changes in Gut Microbiota Composition after Bariatric Surgery: a New Balance to Decode.

Authors:  Silvia Palmisano; Giuseppina Campisciano; Marta Silvestri; Martina Guerra; Michela Giuricin; Biagio Casagranda; Manola Comar; Nicolò de Manzini
Journal:  J Gastrointest Surg       Date:  2019-08-06       Impact factor: 3.452

10.  Association of gestational diabetes mellitus with changes in gut microbiota composition at the species level.

Authors:  Fang Chen; Yu Gan; Yingtao Li; Wenzhi He; Weizhen Wu; Kejian Wang; Qing Li
Journal:  BMC Microbiol       Date:  2021-05-14       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.